CTLA4 and melanoma: Homozygosity in at least one HLA-I locus in patients treated with anti-CTLA-4, anti-PD-1, anti-PD-L1 or with a combination of ICIs for different types of cancer (mostly melanoma and NSCLC) is associated with shorter overall survival.